Skip to content

US · IPHA · BIOTECHNOLOGY

Innate Pharma S.A. (IPHA) intrinsic value and stock valuation

$0.86as of 2026-11-21 · Mkt cap 166.21M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Innate Pharma S.A. DCF and intrinsic value

InvestorsCraft values IPHA with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from IPHA’s statements →

Innate Pharma S.A. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Marseille, PA 13009 innate-pharma.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$2.79M-47.5% 5y CAGRd
20112025
Net income
-$-49.18M
20112025
Free cash flow
-$-34.91M
20112025
Total equity
-$-21.69M
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$2.79M$12.6M$51.9M$57.7M$12.1M
Operating income-$-53.42M-$-51.58M-$-12.67M-$-57.42M-$-47.83M
Net income-$-49.18M-$-49.47M-$-7.57M-$-58.1M-$-52.81M
EPSd-$-549.99K-$-610.36K-$-90K-$-729.53K-$-663.94K
Operating cash flow-$-32.56M-$-6.9M-$-32.56M-$-19.15M-$-58.46M
Capital expenditure-$-2.35M-$-390K-$-2.35M-$-1.12M-$-1.33M
Free cash flow-$-34.91M-$-7.29M-$-34.91M-$-20.28M-$-59.79M
Total assets$62.7M$111.1M$175.2M$207.9M$267.5M
Total debt$22.6M$31M$39.9M$42.3M$44.3M
Net debt-$-5.52M-$-35.4M-$-30.71M-$-41.97M-$-59.51M
Total equity-$-21.69M$8.83M$51.9M$54.2M$107.4M
Cash and short-term investments$34.3M$80.8M$92.5M$101.5M$119.8M
Income statement
20252024202320222021
Revenue$2.79M$12.6M$51.9M$57.7M$12.1M
Cost of revenue$0.00$52M$56M$51.7M$47M
Gross profit$2.79M$12.6M$5.62M$6.01M-$-22.3M
Research and development expenses$43.6M$52M$56M$51.7M$47M
Selling, general and administrative expenses$11M$11.9M$11.8M$14.5M$25.5M
Other expenses$1.59M$280K-$-49.48M-$-2.7M-$-47M
Operating expenses$56.2M$64.2M$18.3M$63.4M$25.5M
Cost and expenses$56.2M$64.2M$74.3M$115.1M$59.9M
Interest income$1.32M$2.44M$3.18M$550K$330K
Interest expense$440K$570K$640K$290K$310K
Depreciation and amortization$5.09M$1.99M$5.09M$45.4M$4.6M
Ebitda-$-43.65M-$-46.91M-$-1.84M-$-12.28M-$-43.23M
Operating income-$-53.42M-$-51.58M-$-12.67M-$-57.42M-$-47.83M
Total other income/expenses, net$4.25M$2.1M$5.1M-$-550K$2.35M
Income before tax-$-49.18M-$-49.47M-$-7.57M-$-57.97M-$-45.48M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-49.18M-$-49.47M-$-7.57M-$-58.1M-$-52.81M
Weighted average shares outstanding$89.4M$81.1M$84.1M$79.6M$79.5M
Weighted average diluted shares outstanding$89.4M$81.1M$84.1M$79.6M$79.5M
Balance sheet
20252024202320222021
Cash and short-term investments$34.3M$80.8M$92.5M$101.5M$119.8M
Net receivables$7.61M$1.64M$46.5M$3.14M$1.66M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$46.7M$85.7M$148M$139.8M$138.3M
Property, plant and equipment, net$4.35M$5.13M$6.32M$8.54M$10.2M
Goodwill and intangible assets$0.00$0.00$420K$1.56M$44.2M
Long-term investments$10.7M$10.3M$9.8M$35.1M$39.9M
Total non-current assets$16M$25.3M$27.2M$68M$129.2M
Total assets$62.7M$111.1M$175.2M$207.9M$267.5M
Accounts payable$15M$7.92M$8.56M$13.7M$14.7M
Short-term debt$8.8M$8.71M$8.94M$2.1M$30.8M
Deferred revenue$2.82M$620K$5.87M$6.56M$12.5M
Total current liabilities$36.6M$33M$39.6M$41.3M$79.9M
Long-term debt$13.8M$22.3M$31M$40.2M$13.5M
Deferred revenue, non-current$0.00$2.83M$4.62M$7.92M$25.4M
Total non-current liabilities$47.8M$69.2M$83.7M$112.4M$80.2M
Capital lease obligations$380K$380K$830K$2.06M$2.82M
Total liabilities$84.4M$102.2M$132.3M$153.7M$160.1M
Common stock$4.69M$4.19M$4.04M$4.01M$3.98M
Retained earnings-$-435.36M-$-386.36M-$-336.89M-$-330.32M-$-272.21M
Accumulated other comprehensive income (loss)$1.12M$30K$490K$820K$460K
Total equity-$-21.69M$8.83M$51.9M$54.2M$107.4M
Total investments$16.9M$24.7M$31.7M$52.4M$56M
Total debt$22.6M$31M$39.9M$42.3M$44.3M
Net debt-$-5.52M-$-35.4M-$-30.71M-$-41.97M-$-59.51M
Cash flow statement
20252024202320222021
Net income-$-7.57M-$-49.47M-$-7.57M-$-58.1M-$-52.81M
Depreciation and amortization$5.09M$1.99M$5.09M$45.4M$4.6M
Stock-based compensation$4.26M$3.94M$4.26M$4.25M$2.62M
Change in working capital-$-32.09M$47.7M-$-32.09M-$-12.5M-$-9.88M
Accounts receivable$0.00$51.8M-$-13.67M-$-4.2M$3.39M
Inventory$0.00$0.00$0.00$0.00-$-6.27M
Accounts payable$0.00$0.00-$-3.89M-$-7.66M-$-950K
Net cash provided by operating activities-$-32.56M-$-6.9M-$-32.56M-$-19.15M-$-58.46M
Investments in property, plant and equipment-$-350K-$-390K-$-350K-$-1.12M-$-1.33M
Acquisitions, net$0.00$0.00$0.00$0.00$10K
Net cash used for investing activities$20.6M$9.2M$20.6M$1.88M-$-920K
Common stock issued$400K$2.93M$400K$200K$500K
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-1.97M-$-6.01M-$-1.97M-$-1.83M$26.8M
Net change in cash-$-13.62M-$-4.21M-$-13.62M-$-19.53M-$-33.04M
Cash at end of period$70.6M$66.4M$70.6M$84.2M$103.8M
Operating cash flow-$-32.56M-$-6.9M-$-32.56M-$-19.15M-$-58.46M
Capital expenditure-$-2.35M-$-390K-$-2.35M-$-1.12M-$-1.33M
Free cash flow-$-34.91M-$-7.29M-$-34.91M-$-20.28M-$-59.79M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Innate Pharma S.A.

        Innate Pharma S.A. is a biotechnology firm, founded in 1999 and headquartered in Marseille, France, that specializes in the discovery, development, and market introduction of therapeutic antibodies. The company primarily targets oncology indications across France and internationally, with some programs also addressing inflammatory diseases and viral infections. Its clinical-stage pipeline features several key assets: Lacutamab (IPH4102): An anti-KIR3DL2 antibody undergoing Phase II trials for cutaneous T-cell and peripheral T-cell lymphoma, and also for refractory Sézary syndrome. Monalizumab: An immune checkpoint inhibitor currently in Phase III clinical trials for various advanced solid tumors, including colorectal, lung, and head and neck cancers. Avdoralimab (IPH5401): A monoclonal antibody designed to block C5a binding to C5aR1, which is in Phase II development for COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory conditions. IPH5201: A blocking antibody in Phase I trials, focused on the CD39 immunosuppressive pathway. IPH5301: An anti-CD73 antibody developed to enhance anti-tumor immunity by targeting the immunosuppressive adenosine pathway. IPH6101: An NKp46-based NK cell engager being evaluated for the generation of up to two bispecific NK cell engagers. Innate Pharma also maintains an active preclinical pipeline, including IPH43 (an anti-MICA/B antibody drug conjugate), an Anti-Siglec-9 antibody program, IPH65 (a proprietary tetraspecific antibody), IPH25 (a checkpoint inhibitor), and the IPH62 and IPH64 programs. The company has established strategic licensing and collaboration agreements with major industry players such as AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech, alongside a co-development and license agreement with MedImmune Limited.

        CEO
        Jonathan E. Dickinson
        Employees
        163
        Beta
        0.88

        Explore

        Frequently asked questions

        What is the intrinsic value of Innate Pharma S.A. (IPHA)?

        InvestorsCraft does not currently publish an intrinsic value for IPHA. How the IC value is calculated.

        Is IPHA undervalued?

        InvestorsCraft does not publish an undervaluation signal for IPHA at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.